A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine

3区 · 医学

Article

作者: Granoff, Dan M ; Lujan, Eduardo ; Pajon, Rolando

BACKGROUNDMeningococcal epidemics in Sub-Sahara caused by serogroup A strains are controlled by a group A polysaccharide conjugate vaccine. Strains with serogroups C, W and X continue to cause epidemics. Protein antigens in licensed serogroup B vaccines are shared among serogroup B and non-B strains.PURPOSECompare serum bactericidal antibody responses elicited by an investigational native outer membrane vesicle vaccine with over-expressed Factor H binding protein (NOMV-FHbp) and a licensed serogroup B vaccine (MenB-4C) against African serogroup A, B, C, W and X strains.METHODSHuman Factor H (FH) transgenic mice were immunized with NOMV-FHbp prepared from a mutant African meningococcal strain containing genetically attenuated endotoxin and a mutant sub-family B FHbp antigen with low FH binding, or with MenB-4C, which contains a recombinant sub-family B FHbp antigen that binds human FH, and three other antigens, NHba, NadA and PorA P1.4, capable of eliciting bactericidal antibody.RESULTSThe NOMV-FHbp elicited serum bactericidal activity against 12 of 13 serogroup A, B, W or X strains from Africa, and four isogenic serogroup B mutants with sub-family B FHbp sequence variants. There was no activity against a serogroup B mutant with sub-family A FHbp, or two serogroup C isolates from a recent outbreak in Northern Nigeria, which were mismatched for both PorA and sub-family of the FHbp vaccine antigen. For MenB-4C, NHba was expressed by all 16 African isolates tested, FHbp sub-family B in 13, and NadA in five. However, MenB-4C elicited titers ≥ 1:10 against only one isolate, and against only two of four serogroup B mutant strains with sub-family B FHbp sequence variants.CONCLUSIONSNOMV-FHbp has greater potential to confer serogroup-independent protection in Africa than the licensed MenB-4C vaccine. However, the NOMV-FHbp vaccine will require inclusion of sub-family A FHbp for coverage against recent serogroup C strains causing outbreaks in Northern Nigeria.

2014-02-01·Bulletin de la Société de pathologie exotique

Impact d’un vaccin conjugué antiméningococcique « A » sur les méningites bactériennes notifiées à l’ouest du Burkina Faso (2009–2012)

Article

作者: A Drabo ; S Sanou ; M Schlumberger ; A S Ouédraogo ; R Ouedraogo ; T M Yaméogo ; S Ouangraoua ; S Yaro

Burkina Faso is a sub-saharan African country completely included in the meningococcal meningitis belt. The western part of the country suffered from many meningococcal A epidemics, in spite of reactive collective campaigns with polysaccharide A vaccine. On 6th December 2010, Burkina Faso was the first African country to conduct a collective vaccination campaign of all the 1-29 years old population with a new conjugated meningococcal Avaccine (MenAfriVac™). Before this campaign, in Western Burkina (4,064,928 inhabitants, 27.5% of total population), a rehearsal of the staff of all peripheral medical laboratories has been conducted, with delivery of laboratory equipment, reactants, and possibility to transfer CSF specimens at the central level to confirm bacteriologic species in cause by latex, culture and PCR analysis. For this campaign, an administrative coverage of 100.3% was reached. A nearly complete disappearance of meningitis due to meningococcus A was recorded, but an increase of cases due to meningococcus X, W135. With the increase of quality of surveillance, and MenAfriVac™ vaccination showed its beneficial effect on meningococcus A meningitis. If we want however to impact on the number of recorded acute bacteriological meningitis, we will have to use multi-antigenic, if possible conjugated, meningococcal vaccines against locally circulating meningococcal species, the number of pneumococcal meningitis being contained by the recent inclusion in EPI of a 13-valent conjugated pneumococcal vaccine.

2001-07-01·The Lancet1区 · 医学

Oesophageal varix bleed

1区 · 医学

Article

作者: Mishriki, Y Y

23 Caugant DA. Population genetics and molecular epidemiology of Neisseria meningitidis. APMIS 1998; 106: 505–25. 24 Spiegel A, Greindl I, Bordonado JL, et al. Fiabilite du diagnostic de meningite cerebospinale en periode epidemique. A propos de l’epidemie de Tchad en 1988. Bull Soc Pathol Exot 1990; 83: 642–48. 25 Lewis R, Nathan N, Communier A, et al. Mieux detecter les epidemies de meningite a meningocoque en Afrique: une nouvelle recommendation. Cahiers Sante (in press). 26 Wenger J, Tikhomirov E, Barakamfitiye D, Bele O, Heymann DL. Meningococcal vaccine in sub-Saharan Africa. Lancet 1997; 350: 1709. 27 Kaninda AV, Varaine F, Henkens M, Paquet C. Meningococcal vaccine in sub-Saharan Africa. Lancet 1997; 350: 1708. 28 Reingold AL, Hightower AW, Bolan GA, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985; 2: 114–18. 29 MacLennan J, Obaro S, Deeks J, et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine 1999; 17: 3086–93. 30 Hassan-King MKA, Wall RA, Greenwood BM. Meningococcal carriage, meningococcal disease and vaccination. J Infect 1988; 16: 55–59. 31 Blakebrough IS, Greenwood BM, Whittle HC, Bradley AK. Failure of meningococcal vaccination to stop the transmission of meningococci in Nigerian schoolboys. Ann Trop Med Parasitol 1983; 77: 175–78. 32 Campagne G, Garba A, Fabre P, et al. Safety and immunogenicity of three doses of a Neisseria meningitidis A+C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J 2000; 19: 144–50. ARTICLES

100 项与 A群脑炎球菌多糖 (浙江天元生物) 相关的药物交易

登录后查看更多信息